Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study
Marquita Camilleri(University College London Hospitals NHS Foundation Trust), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Jonathan Sive(University College London Hospitals NHS Foundation Trust), Elizabeth H. Phillips(University of Manchester), James D. Cavenagh(National Health Service), Gordon Cook(University of Leeds), Laura Clifton‐Hadley(Cancer Research UK), Marie Scully(University College Hospital), Ceri Bygrave(Cardiff and Vale University Health Board), Matthew Streetly(King's College - North Carolina), Gavin Pang(Cancer Research UK), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Lydia Eccersley(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Karthik Ramasamy(Oxford University Hospitals NHS Trust), Richard G. Jenner(Cancer Research UK), M.D. Chapman, Michael Sheaff(Moorfields Eye Hospital NHS Foundation Trust), Rakesh Popat(University College London Hospitals NHS Foundation Trust), Sumaiya Kamora(Cancer Research UK), Selina J Chavda(University College London), Andres Virchis(The Royal Free Hospital), Reuben Benjamin(King's College London), María Cuadrado(University College London), William Wilson(Cancer Research UK)
Cited by 15
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies
|British Journal of Haematology|2012|867
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719